Cantor Fitzgerald Reiterates Entasis Therapeutics (ETTX) at Overweight, Believes More Value to Unlocked in Shares
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $5.00 price target on Entasis Therapeutics (NASDAQ: ETTX), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
